[HTML][HTML] Novel autoantibodies and clinical phenotypes in adult and juvenile myositis
ZE Betteridge, H Gunawardena, NJ McHugh - Arthritis research & therapy, 2011 - Springer
ZE Betteridge, H Gunawardena, NJ McHugh
Arthritis research & therapy, 2011•SpringerAutoantibodies targeting intracellular proteins involved in key processes are detected in
patients with idiopathic inflammatory myopathies. These myositisspecific autoantibodies
have been increasingly demonstrated to correlate with distinct clinical phenotypes within the
myositis spectrum. This review highlights the clinical associations of the myositisspecific
autoantibodies, with particular attention to the recently identified and characterized novel
myositis autoantibodies: p155/140, p140 (MJ), CADM-140 (MDA5), SAE, and 200/100.
patients with idiopathic inflammatory myopathies. These myositisspecific autoantibodies
have been increasingly demonstrated to correlate with distinct clinical phenotypes within the
myositis spectrum. This review highlights the clinical associations of the myositisspecific
autoantibodies, with particular attention to the recently identified and characterized novel
myositis autoantibodies: p155/140, p140 (MJ), CADM-140 (MDA5), SAE, and 200/100.
Abstract
Autoantibodies targeting intracellular proteins involved in key processes are detected in patients with idiopathic inflammatory myopathies. These myositisspecific autoantibodies have been increasingly demonstrated to correlate with distinct clinical phenotypes within the myositis spectrum. This review highlights the clinical associations of the myositisspecific autoantibodies, with particular attention to the recently identified and characterized novel myositis autoantibodies: p155/140, p140 (MJ), CADM-140 (MDA5), SAE, and 200/100.
Springer